Skip to main content

Table 1 Demographic and clinical characteristics of NSCLC patients associated with AFR

From: Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy

Parameters

AFR ≤ 8.02

AFR > 8.02

p value

No. of patients

151

119

–

Age (years)

60.1 ± 10.7

58.5 ± 10.8

0.226

Gender (n, %)

  

0.180

 Male

102(67.5)

71(59.7)

–

 Female

49(32.5)

48(40.3)

–

Current smokers (n, %)

81(53.6)

52(43.7)

0.105

Alcohol (n, %)

34(22.5)

21(17.6)

0.308

Diabetes (n, %)

25(16.6)

13(10.9)

0.186

Hypertension (n, %)

32(21.2)

20(16.8)

0.364

ECOG PS (n, %)

  

0.641

 0

100(66.2)

82(68.9)

–

  ≥ 1

51(33.8)

37(31.1)

–

Location of primary tumor (n, %)

  

0.586

 Left

71(47.0)

52(43.7)

–

 Right

80(53.0)

67(56.3)

–

Tumor size (n, %)

  

0.391

 T1/T2

72(47.7)

63(52.9)

–

 T3/T4

79(52.3)

56(47.1)

–

Lymph node (n, %)

  

0.089

 N0

20(13.2)

25(21.0)

–

 N1–3

131(86.8)

94(79.0)

–

Metastasis stage (n, %)

  

0.709

 M0

45(29.8)

33(27.7)

–

 M1a/M1b

106(70.2)

86(72.3)

–

TNM stage (n, %)

  

0.709

 III

45(29.8)

33(27.7)

–

 IV

106(70.2)

86(72.3)

–

Differentiation (n, %)

  

0.039*

 Well/moderate

36(23.8)

42(35.3)

–

 Poor

115(76.2)

77(64.7)

–

Histology (n, %)

  

0.448

 SCC or others

104(68.9)

87(73.1)

–

 AC

47(31.1)

32(26.9)

–

Chemotherapy (n, %)

  

0.085

 DP

90(59.6)

83(69.7)

–

 AP/GP

61(40.4)

36(30.3)

–

EGFR status

  

0.95

 Wide-type

77(51.0)

63(52.9)

–

 Mutation

43(28.5)

33(27.7)

–

 Unknown

31(20.5)

23(19.3)

–

EML4-ALK status

  

0.93

 Wide-type

102(67.5)

83(69.7)

–

 Mutation

18(11.9)

13(10.9)

–

 Unknown

31(20.5)

23(19.3)

–

K-ras status

  

0.77

 Wide-type

93(61.6)

78(65.5)

–

 Mutation

27(17.9)

18(15.1)

–

 Unknown

31(20.5)

23(19.3)

–

Clinical response (n, %)

  

0.015*

 CR/PR/SD

99(65.6)

94(79.0)

–

 PD

52(34.4)

25(21.0)

–

Laboratory tests (n, %)

 Hemoglobin (g/L)

104.1 ± 13.3

106.3 ± 14.1

0.190

 Platelet (109/L)

177.4 ± 62.3

181.5 ± 75.8

0.626

 WBC(109/L)

7.2 ± 2.4

7.4 ± 2.6

0.513

 CRP (ng/L)

8.4 ± 11.3

5.3 ± 9.7

0.018*

  1. NSCLC Non–small cell lung cancer, AFR Albumin-to-fibrinogen ratio, ECOG PS Eastern cooperative oncology group performance status, TNM Tumor–node–metastasis, SCC Squamous carcinoma, AC Adenocarcinoma, DP Docetaxel combined with platinum, AP Pemetrexed combined with platinum, GP Gemcitabine combined with platinum, CR Complete response, PR Partial response, SD Stable disease, PD Progressive disease, WBC White blood cell, CRP C-reactive protein. P-values were calculated by Student’s t test, Mann–Whitney U test or Chi-squared test. * P < 0.05
Back to article page